David Hamilton, OD
Ophthalmology · Los Angeles, CANPI 1851315626
Payments from drug & device makers
Across 541 payments — averaging $669.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$204K
- Carl Zeiss Meditec, Inc.$131K
- Rxsight Inc$9K
- Carl Zeiss Meditec USA, Inc.$3K
- Alcon Research LLC$3K
- Glaukos Corporation$2K
- plus $10K from 28 others
Across 2 payments — averaging $7290.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec, Inc.$15K
What the payments were for
- Consulting fees$272,29076%
- Speaking & faculty fees$44,22612%
- Travel & lodging$20,7996%
- Food & beverage$21,6666%
- Education$50%
- Gifts$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 158 | $204,329 |
| Carl Zeiss Meditec, Inc. | 69 | $130,631 |
| Rxsight Inc | 27 | $8,892 |
| Carl Zeiss Meditec USA, Inc. | 17 | $3,242 |
| Alcon Research LLC | 2 | $3,000 |
| Glaukos Corporation | 17 | $2,045 |
| Alcon | 34 | $1,912 |
| Lensar, Inc. | 4 | $1,412 |
| Sun Pharmaceutical Industries Inc. | 28 | $1,008 |
| AbbVie(2 entities) | 38 | $892 |
| Novartis | 37 | $732 |
| Bausch & Lomb Americas Inc. | 28 | $565 |
| Tarsus Pharmaceuticals, Inc. | 14 | $503 |
| NEW World Medical,inc. | 7 | $411 |
| Optos, Inc. | 3 | $361 |
| Beaver-visitec International, Inc. | 3 | $336 |
| Sight Sciences, Inc. | 5 | $252 |
| Nova Eye, Inc. | 2 | $251 |
| Biotissue Holdings Inc. | 2 | $239 |
| Kala Pharmaceuticals, Inc. | 13 | $201 |
| Oyster Point Pharma, Inc. | 6 | $157 |
| Omeros Corporation | 2 | $137 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $123 |
| Dompe US, Inc. | 3 | $92 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Shire North American Group Inc | 2 | $49 |
| Harrow Eye, LLC | 2 | $46 |
| Ocular Therapeutix, Inc. | 2 | $44 |
| Galderma Laboratories, L.p. | 2 | $42 |
| Rayner Intraocular Lenses Limited | 2 | $41 |
| Amgen | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Abiomed | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$114,804
- Tecnis Multifocal Family of 1-piece IOLS$82,788
- Tecnis IOL$71,764
- Compact Intuitiv$64,945
- Healon Duet Pro$64,945
- Tecnis Toric 1-piece IOL$43,480
- CATALYS SYSTEM$30,871
- Healon Viscoelastics$29,906
- Tecnis Symphony IOL$24,472
- Tecnis Symphony Toric IOL$24,472
- Tecnis 1-piece IOL$21,121
- Tecnis 3-piece IOL$21,121
- Catalys Laser System$14,540
- COMPACT INTUITIV Phacofragmentation System$8,906
- RXSIGHT CONTACT LENS$8,324
- RXSIGHT INJECTOR CARTRIDGE$8,324
- RXSIGHT INJECTOR HANDPIECE$8,324
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$8,324
- LIGHT ADJUSTABLE LENS (LAL)$7,529
- VERACITY SURGICAL$6,856
How this compares
$362,067 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 36 | $37,245 |
| RestasisCyclosporine | 21 | $22,534 |
| CequaCyclosporine | 16 | $15,567 |
| MieboPerfluorohexyloctane/Pf | 11 | $7,902 |
| Prednisolone Acetate | 55 | $1,932 |
| Latanoprost | 34 | $195 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $565 | $45,14747 claims |
| AbbVieRestasis | $892 | $22,53421 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,008 | $15,56716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Steven JacobsonLos Angeles$4.7M
- David BoyerLos Angeles$4M
- Firas RahhalLos Angeles$1.2M
- Nicole FramLos Angeles$1.2M
- Andrew MoshfeghiLos Angeles$1M
- Pradeep PrasadLos Angeles$901K
- Barry SeibelLos Angeles$835K
- David LiaoLos Angeles$722K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.